MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perregaux, D. G.
Right arrow Articles by Gabel, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perregaux, D. G.
Right arrow Articles by Gabel, C. A.

Inhibition of interleukin-1 beta production by SKF86002: evidence of two sites of in vitro activity and of a time and system dependence

DG Perregaux, D Dean, M Cronan, P Connelly and CA Gabel

Department of Cancer, Pfizer Inc., Groton, Connecticut 06340, USA.

Cytokine-suppressing anti-inflammatory drugs (CSAIDs) are reported to inhibit production of proinflammatory cytokines such as interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) by affecting a stress-induced kinase. To gain a better understanding of the selectivity and cellular dynamics of this type of inhibitor, we studied in vitro the prototype member of this class of agents, SKF86002. Lipopolysaccharide (LPS)-activated human monocytes treated with SKF86002 produced less proIL-1 beta but normal amounts of the noncytokine lysozyme. Two-dimensional gel analysis indicated that only eight polypeptides produced by monocytes were decreased by SKF86002. Inhibition of IL-1 beta production was achieved by affecting two separate steps in this cytokine's biogenesis. First, SKF86002 lowered proIL-1 beta synthesis. By pulse-chase analysis, this effect was localized to a posttranscriptional site of action; maximal inhibition was observed when SKF86002 was added at the time of cytokine translation. Exposure of monocytes to SKF86002 for > 2 hr led to a loss of IL-1 beta inhibitory activity, suggesting that these cells adapted to this agent. Moreover, LPS-activated monocytes that were pretreated with granulocyte-macrophage colony-stimulating factor were less sensitive to the proIL-1 beta inhibitory effect of SKF86002, and production of proIL-1 beta by cytokine-stimulated human fibroblasts was impaired only modestly by the CSAID. A second effect of SKF86002 was to inhibit release of IL-1 beta into the medium in response to high concentrations of LPS; this effect is observed only with freshly isolated human monocytes as other IL-1 beta-producing cells do not release significant cytokine in response to LPS. The ability of SKF86002 to inhibit this posttranslational mechanism was mimicked by lysosomotrophic agents such as chloroquine, quinacrine, and methylamine. In contrast, chloroquine, and quinacrine were not effective inhibitors of monocyte proIL-1 beta translation. Thus, SKF86002 inhibits IL-1 beta production by affecting at least two distinct steps in the biosynthesis of this cytokine. Manifestation of these two effects, however, is dependent on the length of time for which cells are exposed to this agent and the nature of the cytokine- producing cellular system.

Volume 48, Issue 3, pp. 433-442, 09/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Immunol.Home page
Y. J. Kang, J. Chen, M. Otsuka, J. Mols, S. Ren, Y. Wang, and J. Han
Macrophage Deletion of p38{alpha} Partially Impairs Lipopolysaccharide-Induced Cellular Activation
J. Immunol., April 1, 2008; 180(7): 5075 - 5082.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Chabaud-Riou and G. S. Firestein
Expression and Activation of Mitogen-Activated Protein Kinase Kinases-3 and -6 in Rheumatoid Arthritis
Am. J. Pathol., January 1, 2004; 164(1): 177 - 184.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
M.H.F. Sullivan, S.A. Alvi, N.L. Brown, M.G. Elder, and P.R. Bennett
The effects of a cytokine suppressive anti-inflammatory drug on the output of prostaglandin E2 and interleukin-1{beta} from human fetal membranes
Mol. Hum. Reprod., March 1, 2002; 8(3): 281 - 285.
[Abstract] [Full Text] [PDF]


Home page
Innate ImmunityHome page
Y. Vodovotz, Shubing Liu, C. McCloskey, R. Shapiro, A. Green, and T. R. Billiar
The hepatocyte as a microbial product-responsive cell
Innate Immunity, October 1, 2001; 7(5): 365 - 373.
[Abstract] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
W. Zhu, M. A. Brauchle, F. Di Padova, H. Gram, L. New, K. Ono, J. S. Downey, and J. Han
Gene suppression by tristetraprolin and release by the p38 pathway
Am J Physiol Lung Cell Mol Physiol, August 1, 2001; 281(2): L499 - L508.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
M. Allen, L. Svensson, M. Roach, J. Hambor, J. McNeish, and C. A. Gabel
Deficiency of the Stress Kinase p38{alpha} Results in Embryonic Lethality: Characterization of the Kinase Dependence of Stress Responses of Enzyme-deficient Embryonic Stem Cells
J. Exp. Med., March 6, 2000; 191(5): 859 - 870.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1995 by the American Society for Pharmacology and Experimental Therapeutics